– CANADA, Halifax – IMV Inc. (Nasdaq:IMV / TSX:IMV), a clinical stage immunotherapy company, announced today the addition of Julia P. Gregory to the company’s Board of Directors.
Andy Sheldon, IMV Chairman of the Board, commented, “Julia’s experience is an ideal addition to our Board given the Company’s anticipated near-term milestones and long-term strategic vision. She brings a uniquely rich background in the strategic financing, planning, partnering, and growth of public biotech companies. We are eager to leverage her counsel as our immuno-oncology programs enter another significant stage of growth.”
“It is with great enthusiasm that I join Andy and the other members of the Board to work with IMV’s world-class research and drug development teams on a new class of transformative immunotherapies,” stated Ms. Gregory. “I look forward to the opportunity to work with IMV as the company advances its clinical programs and candidates to address some of the most significant unmet needs in the cancer treatment landscape.”
Ms. Gregory is a seasoned biotechnology executive with Chief Executive Officer, Chief Financial Officer, Board and investment banking experience. She recently served as Chief Executive Officer and Board Member of ContraFect Corporation, a public biotechnology company developing innovative anti-infectives. Prior to this engagement, she served as the Chief Executive Officer of the immuno-oncology company Five Prime.
Ms. Gregory has a proven track record of successfully growing, capitalizing, and positioning private and public biotechnology companies. As a biotechnology executive, she has raised more than $1.5 billion across all types of business cycles and structured creative strategic alliances and transactions with pharmaceutical companies including GlaxoSmithKline, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company, Ltd., Genentech, Inc. (now Roche), and Human Genome Sciences (now GSK). She is currently on the Board of Directors of Iconic Therapeutics, the Sosei Group and Biohaven Therapeutics.
About IMV
IMV Inc., formerly Immunovaccine, is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the reprogramming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently conducting three Phase 2 studies with Incyte and Merck assessing DPX-Survivac as a combination therapy in ovarian cancer and diffuse large B-cell lymphoma.
For more information :
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
